ZD 4927
Latest Information Update: 11 Dec 2001
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis; Thrombosis
Most Recent Events
- 11 Dec 2001 Discontinued-I for Deep vein thrombosis in United Kingdom (Unknown route)
- 11 Dec 2001 Discontinued-I for Thrombosis in United Kingdom (Unknown route)
- 13 Dec 1999 Phase-I clinical trials for Deep vein thrombosis in United Kingdom (Unknown route)